Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review
Hsu P, Singh K, Dhiman A, Witmer H, He C, Eng O, Catenacci D, Posner M, Turaga K. Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology 2022, 6: e2100337. PMID: 35188804, PMCID: PMC8984241, DOI: 10.1200/po.21.00337.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalGI cancersGroup 2Tumor DNACurative-intent surgical resectionDecreased RFSGroup 1Median recurrence-free survivalMeasurement of circulating tumor DNAEarly detection of recurrenceGroup 3Measurement of cell-free DNAPrognosis of GI cancersDetection of recurrenceCirculating tumor DNARisk of recurrenceCell-free DNARisk stratification toolCox hazard ratiosAbsence of ctDNACurative resectionCurative surgerySurgical resectionDetectable ctDNATumor markers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply